Transplant-related immunosuppression: A review of immunosuppression and pulmonary infections

Proceedings of the American Thoracic Society

Volumn 2, Issue 5, 2005, Pages 449-455

  Duncan, Michael D ^a   Wilkes, David S ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hematopoietic stem cell transplant; Immunosuppression and pulmonary infections; Solid organ transplant

Indexed keywords

ALEMTUZUMAB; ANTIINFECTIVE AGENT; ANTIMETABOLITE; ANTIVIRUS AGENT; AZATHIOPRINE; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; PYRROLE DERIVATIVE; RAPAMYCIN; RITUXIMAB; SULFANILAMIDE; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BACTERIAL INFECTION; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LUNG INFECTION; LYMPHOCYTOPENIA; MORBIDITY; MORTALITY; NONHUMAN; ORGAN TRANSPLANTATION; PARASITE; PATHOGENESIS; PROTOZOON; T LYMPHOCYTE; VIRUS INFECTION;

FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; ORGAN TRANSPLANTATION; PNEUMONIA; PROGNOSIS; RISK ASSESSMENT; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 31144473159     PISSN: 15463222     EISSN: 15463222     Source Type: Journal    
DOI: 10.1513/pats.200507-073JS     Document Type: Conference Paper

References (58)

1. Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, Mestroni L, Page RL II, Kobashigawa J. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation 2004;110:3734-3740.
2. Thorsby E, Pfeffer P, Leivestad T. Role of HLA molecules in the induction of alloimmune responses: clinical significance in the cyclosporine era. Transplant Proc 2004;36:16S-21S.
3. Norman D, Turka L. Primer on transplantation, 2nd ed. Mt. Laurel, NJ: American Society of Transplantation; 2001.
4. Haberal M, Emiroglu R, Dalgic A, Karakayli H, Moray G, Bilgin N. The impact of cyclosporine on the development of immunosuppressive therapy. Transplant Proc 2004;36:143S-147S.
5. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004;36:25S-32S.
6. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 2005;24:119-130.
7. Lee YR, Yang IH, Lee YH, Im SA, Song S, Li H, Han K, Kim K, Eo SK, Lee CK. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 2005;105:3951-3955.
8. Baan CC, Balk AH, van Riemsdijk IC, Vantrimpont PJ, Maat AP, Niesters HG, Zondervan PE, van Gelder T, Weimar W. Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation. Transplantation 2003;75:1704-1710.
9. David KM, Morris JA, Steffen BJ, Chi-Burris KS, Gotz VP, Gordon RD. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant 2005;19:279-285.
10. Eisen HJ, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R, Alderman E, Valantine H, Dureau G, Mancini D, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005;24:517-525.
11. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-2729.
12. Lederer SR, Friedrich N, Banas B, Welser G, Albert ED, Sitter T. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation. Clin Transplant 2005;19:168-174.
13. Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004;18:485-492.
14. Ingle GR, Sievers TM, Holt CD. Sirolimus: continuing the evolution of transplant immunosuppression. Ann Pharmacother 2000;34:1044-1055.
15. Neumayer HH. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments. Transplantation 2005;79:S72-S75.
16. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997;16:484-492.
17. King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003;75:1437-1443.
18. Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003;63:2803-2835.
19. Kuypers DR, Vanrenterghem YF. Monoclonal antibodies in renal transplantation: old and new. Nephrol Dial Transplant 2004;19:297-300.
20. Platz KP, Braun F, Fandrich F, Kremer B, Mueller AR. IL-2 antagonists: the European perspective. Transplant Proc 2005;37:1783-1784.
21. Usuda M, Fujimori K, Koyamada N, Fukumori T, Sekiguchi S, Kawagishi N, Akamatsu Y, Enomoto Y, Satoh K, Satoh A, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 2005;79:12-16.
22. Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roohipour R, Carreno MR, Roth D, Ruiz P, Kupin W, Rosen A, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004;78:426-433.
23. Watson CJ, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR, Smith KG, Thiru S, Jamieson NV, Hale G, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation: efficacy and safety at five years. Am J Transplant 2005;5:1347-1353.
24. Kunzendorf U, Ziegler E, Kabelitz D. FTY720: the first compound of a new promising class of immunosuppressive drugs. Nephrol Dial Transplant 2004;19:1677-1681.
25. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005;79:1553-1560.
26. Murray JF, Nadel JA. Textbook of respiratory medicine, 3rd ed. Philadelphia: Saunders;2000.
27. Zhang P, Summer WR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. Immunol Rev 2000;173:39-51.
28. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-1751.
29. Snydman DR. Epidemiology of infections after solid-organ transplantation. Clin Infect Dis 2001;33:S5-S8.
30. Cisneros JM, Munoz P, Torre-Cisneros J, Gurgui M, Rodriguez-Hernandez MJ, Aguado JM, Echaniz A. Pneumonia after heart transplantation: a multi-institutional study. Spanish Transplantation Infection Study Group. Clin Infect Dis 1998;27:324-331.
31. Chao NJ, Emerson SG, Weinberg KI. Stem cell transplantation (cord blood transplants). Hematology (Am Soc Hematol Educ Program) 2004. pp. 354-371.
32. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001;33:139-144.
33. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004;170:22-48.
34. Montoya JG, Giraldo LF, Efron B, Stinson EB, Gamberg P, Hunt S, Giannetti N, Miller J, Remington JS. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001;33:629-640.
35. Singh N, Paterson DL, Chang FY, Gayowski T, Squier C, Wagener MM, Marino IR. Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients. Clin Infect Dis 2000;30:322-327.
36. Torres A, Ewig S, Insausti J, Guergue JM, Xaubet A, Mas A, Salmeron JM. Etiology and microbial patterns of pulmonary infiltrates in patients with orthotopic liver transplantation. Chest 2000;117:494-502.
37. Speich R, van der Bij W. Epidemiology and management of infections after lung transplantation. Clin Infect Dis 2001;33:S58-S65.
38. Glanville AR, Gencay M, Tamm M, Chhajed P, Plit M, Hopkins P, Aboyoun C, Roth M, Malouf M. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 2005;24:131-136.
39. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998;27:1266-1277.
40. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis 2001;3:128-137.
41. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004;17:357-361.
42. Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004;4:1219-1226.
43. Dickenmann MJ, Cathomas G, Steiger J, Mihatsch MJ, Thiel G, Tamm M. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 2001;71:764-767.
44. Ramsey PG, Fife KH, Hackman RC, Meyers JD, Corey L. Herpes simplex virus pneumonia: clinical, virologic, and pathologic features in 20 patients. Ann Intern Med 1982;97:813-820.
45. Billings JL, Hertz MI, Wendt CH. Community respiratory virus infections following lung transplantation. Transpl Infect Dis 2001;3:138-148.
46. Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, Mohanakumar T, Trulock EP, Walter MJ. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004;170:181-187.
47. Vilchez RA, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant 2003;3:116-120.
48. Wendt CH. Community respiratory viruses: organ transplant recipients. Am J Med 1997;102:31-36 (Discussion: 42-33).
49. Bag R. Fungal pneumonias in transplant recipients. Curr Opin Pulm Med 2003;9:193-198.
50. Hagerty JA, Ortiz J, Reich D, Manzarbeitia C. Fungal infections in solid organ transplant patients. Surg Infect (Larchmt) 2003;4:263-271.
51. Nicod LP, Pache JC, Howarth N. Fungal infections in transplant recipients. Eur Respir J 2001;17:133-140.
52. Oner-Eyuboglu F, Karacan O, Akcay S, Arslan H, Demirhan B, Haberal M. Invasive pulmonary fungal infections in solid organ transplant recipients: a four-year review. Transplant Proc 2003;35:2689-2691.
53. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999;1:229-236.
54. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001;33:1397-1405.
55. Brown JM. Fungal infections in bone marrow transplant patients. Curr Opin Infect Dis 2004;17:347-352.
56. Chouaki T, Lavarde V, Lachaud L, Raccurt CP, Hennequin C. Invasive infections due to Trichoderma species: report of 2 cases, findings of in vitro susceptibility testing, and review of the literature. Clin Infect Dis 2002;35:1360-1367.
57. Nunley DR, Gal AA, Vega JD, Perlino C, Smith P, Lawrence EC. Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest 2002;122:1185-1191.
58. Teachey DT, Russo P, Orenstein JM, Didier ES, Bowers C, Bunin N. Pulmonary infection with microsporidia after allogeneic bone marrow transplantation. Bone Marrow Transplant 2004;33:299-302.